Vitamin O ? FDA says no
This article was originally published in The Tan Sheet
Executive SummaryR-Garden, marketer of dietary supplement Vitamin O, has been issued a warning letter regarding numerous violations of the FD&C Act, FDA says. Advertising claims made in mailings, customer testimonials and product descriptions found on the firm's website and in literature classify the supplement as a drug, and therefore would require an NDA, the agency states in the Feb. 8 letter. Questionable claims include testimonials that the oxygen-infused salt water, which can be topically applied or internally ingested, "took a skin cancer off my nose," "help[ed] control angina" and "stops gum infection and pain." R-Garden lacks sufficient scientific evidence to back its claims, the agency says, adding the product does not bear adequate dosing instructions, listed ingredients or recommended daily intakes...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.